MD1105
MD1105 is being developed as a disease-modifying therapy in Alzheimer’s disease (undisclosed molecule and mechanism of action). While currently in the pre-clinical phase, MedDay anticipates entering the clinic in early 2015.
MD1105 is being developed as a disease-modifying therapy in Alzheimer’s disease (undisclosed molecule and mechanism of action). While currently in the pre-clinical phase, MedDay anticipates entering the clinic in early 2015.